Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | IDH2 | P48735 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | RAF1 | P04049 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.51 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | DDX3X | O00571 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30822932 | 0.89 | DYRK1A (0.67) | HTTIDH2DYRK1ADYRK1BRAF1 | |
| SCHEMBL1163657 | 0.89 | MEN1 (0.56) | AKR1C3MEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL18415225 | 0.86 | AKR1C3 (0.59) | AKR1C3HTTMEN1KMT2ARAF1 | |
| SCHEMBL1998129 | 0.84 | MTOR (0.67) | AKR1C3MEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL2004629 | 0.84 | MEN1 (0.51) | AKR1C3MEN1KMT2ADYRK1ADYRK1B | |
| SCHEMBL30822892 | 0.84 | HDAC11 (0.60) | HTTIDH2DYRK1ADYRK1BRAF1 | |
| SCHEMBL30933634 | 0.82 | MTOR (0.76) | HTTMEN1KMT2AMTORRAF1 | |
| SCHEMBL30822902 | 0.81 | RAF1 (0.60) | HTTIDH2DYRK1ADYRK1BRAF1 | |
| SCHEMBL30822911 | 0.81 | HTT (0.58) | HTTIDH2RAF1BRAFPTK6 | |
| SCHEMBL2001169 | 0.80 | RAB9A (0.53) | AKR1C3MEN1KMT2ADYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | claimed |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | EDIGENE BIOTECHNOLOGY, INC. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-7960561-B2 | 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2011-06-14 | — | — | US | disclosed |
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | KCNN2, KCNN1, KCNN3 | AKR1C3 3134/4885HTT 4121/4885IDH2 2868/4885 |
| US-20210220408-A1 | ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE | AHR, ARNT, ARSA | AKR1C3 275/4885HTT 687/4885IDH2 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.